Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Three Rivers Pharmaceuticals has finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International. Valeant is receiving $91 million from Three Rivers for the procurement.
Subscribe to our email newsletter
Infergen, or consensus interferon, is a bio-optimized, selective and highly potent type 1 interferon alpha. It is currently indicated as monotherapy for the treatment of adult patients suffering from chronic hepatitis C viral infections with compensated liver disease and is dosed three times per week.
Donald Kerrish, Three River’s president and CEO, said: “Adding Infergen to our growing portfolio is very exciting. This purchase is only a beginning for Three Rivers’s continuous strategy to increase its product offerings through product acquisition and internal product development of pharmaceutical therapies.”